Abstract
Introduction

Mutations in the dystrophin gene can lead to two forms of muscular dystrophy. Null mutations that cause complete loss of dystrophin function typically result in Duchenne muscular dystophy (DMD), a lethal disease characterized by progressive muscle wasting. In-frame deletions that lead to internally deleted dystrophin protein generally result in Becker muscular dystrophy (BMD), which shows milder symptoms than DMD with a large variation in clinical severity.
The finding of patients with a mild form of BMD that have inframe deletions of often large regions of the dystrophin gene, together with the existence of revertant, dystrophin positive fibres in many DMD patients [1] suggests that exclusion of exons harbouring mutations can result in largely functional dystrophin protein. [2] . Currently, clinical trials are underway that are based on administration of exon-skipping antisense oligonucleotides (AO) [3, 4] . In exon skipping, AOs are employed to sterically block exon recognition splice motifs located in the pre-mature transcript. Effective blocking leads to faulty transcript processing that does not splice targeted exons correctly, so that they are excluded from the mature mRNA, resulting in a shorter, but partly to largely functional dystrophin. Although this approach will only be useful for the treatment of a subset of patients, it is estimated that 83% of all DMD patients would theoretically benefit from single or double exon skipping [5] . The exon-skipping approach has shown much promise in recently finished clinical trials [3, 4] . However, these clinical trials were limited, as the AO was only administered locally into a single muscle and healthy volunteers could not be tested due to the possibility of adverse affects on dystrophin function. Exon skipping has also been performed in the mdx mouse and in the golden retriever muscular dystrophy (GRMD) dog [6, 7] , and the efficacy of exon-skipping protocols in generating Dystrophin protein has been demonstrated in both these models. However, the mdx mouse does not resemble the severity of the human condition and a systematic and statistical evaluation of exon skipping in dogs is hampered by their inefficient breeding and phenotypic variety [8] . Therefore, the level of dystrophin function necessary to effect full functional rescue in the context of a severe dystrophin-deficient pathology remains unclear.
Similarly, the functionality of an artificial mini-dystrophin harbouring deletion of exons 18 to 58 has been reported suggesting much of the dystrophin protein may be dispensable for its function
In contrast to the most commonly used model, the mdx mouse [9] , dystrophin-deficient zebrafish, named dmd ta222a [10] , closely resemble the human condition in severity, onset and specific symptoms [11] . The 
Materials and methods
Zebrafish lines and maintenance
The dmd tm90c and dmd ta222a mutant alleles were obtained from the Tübingen Stock Collection [12] . All mutant lines were maintained in the TU (Tübingen) zebrafish strain. Genotyping was accomplished via PCR followed by restriction digestion (Fig. S1 ). All animal experiments were approved by MAS/2009/05.
Non-complementation screen and allele identification
Forty-eight males were mutagenized with N-ethyl-N-nitrosourea (ENU) as described [15] [11] .
Morpholino oligomer injections
Morpholino oligomers were designed and named as described [16] Fig. 2A and B Fig. 2B and C) . (Fig. 3A' ). This birefringence is reduced in dystrophin-deficient zebrafish, as the fibre organization is lost due to detachment and retraction of fibres [10] . Therefore [19] .
Results
Screen for novel dystrophin alleles
Under polarized light the zebrafish muscle shows a birefringence effect that is caused by parallel thread-like myofibrils within muscle fibres
Therefore, the program "RESCUE-ESE" was used to predict ESE located in exon 32 of dystrophin. Based on the prediction, the morpholino Z32E(ϩ133ϩ157) was designed against an ESE positioned close to the 3Ј-end of exon 32. RT-PCR, performed in the same manner as described above, on WT embryos treated with Z32E(ϩ133ϩ157) led to the detection
Fig. 3 Phenotype analysis of morpholino injected dmd pc2/pc2 homozygotes. (A) Although in 3-dpf-old WT larvae antibody against dystrophin locates dystrophin expression at the somite borders (arrowheads), (B) in dmd pc2/pc2 homozygous larvae dystrophin is not detected. (C) In contrast, homozygotes dmd pc2/pc2 treated with Z32A(-18 ϩ 7) show weak dystrophin expression and (D) homozygotes administered with a combination of Z32E(ϩ133ϩ157) and Z32E(ϩ83ϩ107) display robust restoration of dystrophin protein at the somite borders (arrowheads). Although birefringence is evident in WT larvae at 3 dpf, it is reduced in (B') untreated and (C') Z32A(-18 ϩ 7)-injected dmd pc2/pc2 homozygotes. (D') dmd pc2/pc2 homozygotes injected with Z32E(ϩ133ϩ157) and Z32E(ϩ83ϩ107) demonstrate restoration of birefringence, indicating full phenotype rescue. Accordingly, haematoxylin and eosin staining performed on cross-sections of 3-dpf-old larvae shows no phenotypic muscle in (A") WT larvae, whereas the muscle of (B") uninjected and (C") Z32A(-18 ϩ 7)-treated dmd pc2/pc2 homozygous larvae is dystrophic and the phenotype is rescued in larvae (D") administered with Z32E(ϩ133ϩ157) and Z32E(ϩ83ϩ107). The arrow in (B") points to mono-nucleated infiltrates and in (C") to necrotic myofibre. The arrowhead in (C") points to a gap where a necrotic myofibre has been replaced by mucus. Scale bar: 50 m.
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of an additional dystrophin transcript corresponding to the deletion of bp ϩ97 to ϩ174 of exon 32, activating a cryptic splice site at 5Ј-GAG gugaaa-3Ј (Fig. 2D, G 
and H). Therefore, a second morpholino, Z32E(ϩ83ϩ107), was designed to target this region. Administration of Z32E(ϩ83ϩ107) alone promotes inclusion of the intron upstream of exon 32. However, administration of the combined morpholinos Z32E(ϩ133ϩ157) and Z32E(ϩ83ϩ107), in a concentration of 25 M each, induced robust skipping of targeted exon 32 without non-specific morpholino effects. Similar to the result already demonstrated with Z32A(-18 ϩ 7) injection, the proportion of the morpholino-induced transcript in relation to the WT dystrophin transcript is significantly higher in dmd pc2/pc2
homozygotes (93% Ϯ 2%) compared to WT embryos (66% Ϯ 3%; P Ͻ 0.01, n ϭ 3) (Fig. 2G) (Fig. 4) . 
